COMPANY

Privo Technologies

HQ: Peabody, MA source · privotechnologies.com ↗ · New England

Keywords: oncology head and neck cancer Oral Squamous Cell Carcinoma PRV111 (Cisplatin Transmucosal System) PRV211 (Intraoperative Cisplatin System)

Location: Peabody, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)23NIH grants

Funding and NIH signals

NIH award NIH awarded $1.17M (SBIR Phase II 5R44CA281020-09, continuation, notice Jun 18, 2026). NIH RePORTER 5R44CA281020-09 (Jun 18, 2026)
Evidence (1 event)
- Jun 18, 2026 · NIH RePORTER 5R44CA281020-09
  Organization: PRIVO TECHNOLOGIES, LLC; City/State: PEABODY, MA; Project number: 5R44CA281020-09; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-18; FY total cost (award amount): 1170285; Administering IC: National Cancer Institute; Project title: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer); Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 18, 2026 Grant Government grant — SBIR: $1.17M (annual award, as published), announced Jun 18, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Jun 25, 2025 Grant Government grant — SBIR: $1.25M (annual award, as published), announced Jun 25, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Nov 7, 2024 Trial start Phase 2/Phase 3: A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers source ↗
Jun 19, 2018 Trial start Phase 1/Phase 2: Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma source ↗

Upcoming milestones

2026-10 (ESTIMATED) · Phase 2/Phase 3 · A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers · NCT05893888

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jun 18, 2026 Government grant — SBIR: $1.17M (annual award, as published), announced Jun 18, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Jun 25, 2025 Government grant — SBIR: $1.25M (annual award, as published), announced Jun 25, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05893888	A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers	Phase 2/Phase 3	Recruiting	Nov 7, 2024	2026-10 (estimated)
NCT03502148	Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma	Phase 1/Phase 2	Completed	Jun 19, 2018	Oct 27, 2019 (actual)

NIH awards 23

Annual award amounts. Total $18.6M.

Jun 14, 2024 NIH award 2R44CA281020-07A1 FY2024: $2,084,026 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Support for Registration Enabling source ↗
Apr 3, 2024 NIH award 5R44CA272095-03 FY2024: $1,012,303 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Clinical Studies for Improving Survi source ↗
Mar 27, 2023 NIH award 4R44CA272095-02 FY2023: $987,292 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Clinical Studies for Improving Surviva source ↗
Jan 5, 2023 NIH award 5R44DE023725-06 FY2023: $984,664 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Commercialization of Safe and Effectiv source ↗
Feb 24, 2022 NIH award 1R44CA272095-01 FY2022: $401,107 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Clinical Studies for Improving Surviva source ↗
Jan 10, 2022 NIH award 5R44DE023725-05 FY2022: $779,005 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Commercialization of Safe and Effectiv source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N91022C00020-0-9999-1 FY2022: $2,049,944 awarded for that fiscal year; activity N44 (OTHER_NIH); PI GOLDBERG, MANIJEH; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. TOP source ↗
Jun 30, 2021 NIH award 5R01FD006325-03 FY2021: $99,660 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Highly focused loco-regional chemo source ↗
Feb 3, 2021 NIH award 2R44DE023725-04 FY2021: $1,183,038 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Commercialization of Safe and Effect source ↗
Jun 25, 2020 NIH award 5R01FD006325-02 FY2020: $498,400 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Highly focused loco-regional chem source ↗
Jun 22, 2020 NIH award 5R44CA192875-06 FY2020: $1,000,447 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Supportive Clinical Trial Tasks for source ↗
Sep 5, 2019 NIH award 1R01FD006325-01A1 FY2019: $449,307 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Highly focused loco-regional ch source ↗
Jul 19, 2019 NIH award 3R44CA192875-05S1 FY2019: $4,318 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Supportive Clinical Trial Tasks for Na source ↗
Jun 24, 2019 NIH award 5R44CA192875-05 FY2019: $1,083,847 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Supportive Clinical Trial Tasks for source ↗
Jan 11, 2019 NIH award 3R44CA192875-04S1 FY2019: $98,000 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Supportive Clinical Trial Tasks for N source ↗
Jul 17, 2018 NIH award 2R44CA192875-04 FY2018: $999,072 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Supportive Clinical Trial Tasks for Na source ↗
Feb 17, 2017 NIH award 5R44DE023725-03 FY2017: $999,997 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Customized Nanotechnology Based Treatm source ↗
Feb 1, 2017 NIH award 5R44CA192875-03 FY2017: $1,170,342 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. FAST TRACK: IND Enabling Studies for source ↗
Aug 17, 2016 NIH award 3R44DE023725-02S1 FY2016: $265,000 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Customized Nanotechnology Based Trea source ↗
Feb 24, 2016 NIH award 2R44DE023725-02 FY2016: $999,997 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Customized Nanotechnology Based Treatm source ↗
Jan 13, 2016 NIH award 4R44CA192875-02 FY2016: $960,707 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. FAST TRACK: IND Enabling Studies for O source ↗
Jun 12, 2015 NIH award 1R44CA192875-01 FY2015: $293,491 awarded for that fiscal year; activity R44 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. FAST TRACK: IND Enabling Studies for O source ↗
Aug 29, 2014 NIH award 1R43DE023725-01A1 FY2014: $220,675 awarded for that fiscal year; activity R43 (SBIR); PI GOLDBERG, MANIJEH N; recipient as written: PRIVO TECHNOLOGIES, LLC, PEABODY, MA. Customized nanotechnology based trea source ↗